Testing

Hereditary neuromuscular disorders are quite varied in their presentations and even more diverse in terms of their specific genetic causes. Sometimes, these disorders can be framed in terms of the extent of weakness, sensory involvement, and/or autonomic involvements, but in other instances, it may be difficult to discern the appropriate test for many patients based on phenotype.

By mayocliniclabs • April 24, 2018

At Mayo Clinic, we know the importance of laboratory testing in a patient’s episode of care. Our unique combination of specialized laboratories and neurology patient care clinics gives us the ability to put into practice clinically proven, cost-effective, patient care-driven testing approaches for hundreds of neurological conditions.

By mayocliniclabs • April 21, 2018

The following list of updates were posted to MayoMedicalLaboratories.com during the month of March 2018.

By Erika Fetterman • April 20, 2018

Mayo Medical Laboratories is the first clinical laboratory to offer postmortem genetic tests for inheritable cardiovascular disorders on formalin-fixed paraffin-embedded (FFPE) tissue as a preferred sample type.

By mayocliniclabs • April 10, 2018

In March 2018, Mayo Medical Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • April 5, 2018

In February 2018, Mayo Medical Laboratories announced two new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • March 15, 2018

The following list of updates were posted to MayoMedicalLaboratories.com during the month of February 2018.

By Erika Fetterman • March 13, 2018

Multiple myeloma is the second most common blood cancer, but most people haven’t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month—a time to focus attention on the fight against multiple myeloma.

By Barbara J. Toman • March 6, 2018

Mayo Clinic offers a different approach compared to traditional pain-management testing because our Pain Clinic Survey only tests for the most common drugs of abuse, primarily those characterized as Tier I in the American Association for Clinical Chemistry’s laboratory medicine practice guideline. Testing for less-common drugs is only recommended in high-risk patients or when clinically indicated, which leads to more appropriate test utilization, saving ordering institutions time and money.

By mayocliniclabs • March 1, 2018

The following list of updates were posted to MayoMedicalLaboratories.com during the month of January 2018.

By Erika Fetterman • February 13, 2018

In January 2018, Mayo Medical Laboratories announced five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • February 8, 2018

With more than 70,000 uses worldwide and policy endorsements for its use (JAMA Article), the Mayo Clinic Statin Choice Decision-Aid tool is helping patients and their clinicians have meaningful conversations about whether or not to use statins to reduce cardiovascular risk.

By mayocliniclabs • January 25, 2018

  The following list of updates were posted to MayoMedicalLaboratories.com during the month of December […]

By Erika Fetterman • January 14, 2018